Nebilet Plus (Hydrochlorothiazide, Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors, slowing heart rate and reducing cardiac output. It also enhances nitric‑oxide release from the endothelium, causing blood‑vessel relaxation. This dual action lowers systemic vascular resistance and helps control hypertension.

The specific dose of Nebilet Plus is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other medications. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety of Nebilet Plus in pregnancy or while breastfeeding has not been fully established. Healthcare providers usually weigh potential benefits against risks before prescribing. Women who are pregnant, planning pregnancy, or nursing should discuss alternative treatments with their doctor.

To order Nebilet Plus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebilet Plus offers a fixed‑dose combination of a selective β1‑blocker and a thiazide diuretic, simplifying therapy compared with taking two separate tablets. This can improve adherence and provide complementary mechanisms—heart‑rate control and diuresis—whereas other classes such as ACE inhibitors or calcium‑channel blockers act through different pathways.

Nebilet Plus tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Keep them away from moisture, direct sunlight, and out of reach of children to maintain potency and stability.

Nebilet Plus is taken orally, usually once daily, with or without food as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew it unless instructed otherwise.

Serious risks include severe hypotension, acute kidney injury, significant electrolyte disturbances (especially low potassium), and rare allergic reactions such as angioedema. Patients should report symptoms like dizziness, fainting, rapid weight gain, muscle weakness, or rash to their physician promptly.

Nebilet Plus is contraindicated in patients with known hypersensitivity to nebivolol, hydrochlorothiazide, or any component of the formulation. It should also be avoided in individuals with severe renal impairment, uncontrolled electrolyte imbalances, or those taking certain interacting medications without medical supervision.